Current and developing synthetic pharmacotherapy for treating relapsed/refractory multiple myeloma.

Area of Science:

• Hematology
• Oncology
• Pharmacology

Background:

• Multiple myeloma (MM) treatment has seen major advances over the last 20 years, with numerous drug approvals in the US and Europe.
• Key drug classes include proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies, targeting both myeloma cells and the bone marrow microenvironment.
• Combinatorial regimens, integrating novel agents with conventional therapies, are crucial for achieving durable responses, especially in relapsed/refractory MM (RRMM).

Purpose of the Study:

• To summarize landmark discoveries that have advanced MM clinical practice.
• To discuss emerging therapeutic strategies poised to further improve patient outcomes.
• To provide an expert opinion on the current and future landscape of MM treatment.

Main Methods:

• Review of historical therapeutic advancements in multiple myeloma.
• Analysis of current cornerstone therapies and their combinatorial use.
• Discussion of preclinical and early clinical pipeline agents.

Main Results:

• Significant improvements in MM patient outcomes have been achieved through novel therapeutic agents.
• Durable responses, particularly in RRMM, are largely attributed to combination therapies.
• Despite progress, MM remains an incurable malignancy.

Conclusions:

• The combination of novel agents with conventional chemotherapy has revolutionized MM treatment.
• Ongoing research into new agents like CD38 and BCMA mAbs, immune checkpoint inhibitors, and cell-based therapies offers hope for improved patient outcomes.
• Continued innovation in MM therapeutics is essential for overcoming the challenges of this complex disease.